How to Apply to Roivant Sciences

11 min read Last updated April 20, 2026 11 open positions
Blake Crosley
Blake Crosley Researched using publicly available information, hiring data, and ATS analysis.

Key Takeaways

  • Roivant Sciences is a NASDAQ-listed biopharma holding company with a Basel legal headquarters and operating offices in New York, London, and Boston; CEO Matt Gline has run the company since founder Vivek Ramaswamy stepped down in 2021.
  • The hub-and-spoke Vant model means joining Roivant often means joining one specific subsidiary biotech such as Immunovant, Hemavant, Pulmovant, Genevant, Datavant, or Lokavant, each with its own culture and management team.
  • Immunovant (NASDAQ: IMVT), the FcRn antibody company developing batoclimab and IMVT-1402 for autoimmune indications, is the single largest near-term value driver in the portfolio.
  • The September 2024 sale of Dermavant's Vtama to Organon for roughly 1.2 billion dollars upfront fueled aggressive share buybacks and reshaped the equity story toward cash plus the Immunovant stake.
  • Vivek Ramaswamy's political profile, including his 2024 US presidential campaign, brief role in the second Trump administration, and current leadership at Strive Asset Management, is part of the public picture and is sometimes a topic in interviews.
  • Hiring is craft-driven and demanding across both deal-oriented and drug-development functions; Roivant rewards directness, written reasoning, and evidence over pedigree.
  • The bulk of postings flow through a Greenhouse board at boards.greenhouse.io/roivantsciences; standard ATS-friendly resume hygiene applies.
  • Compensation typically combines competitive base, performance bonus, and meaningful equity in either ROIV or, for some Vant-specific roles, the relevant listed Vant such as IMVT, with the usual public company disclosure obligations attached.

About Roivant Sciences

Roivant Sciences Ltd. (NASDAQ: ROIV) is a publicly traded biopharmaceutical holding company built on a hub-and-spoke model. The legal headquarters sits in Basel, Switzerland for tax and corporate-structure reasons, while operating offices and the bulk of working employees are in New York City, London, and Boston. The company was founded in 2014 by Vivek Ramaswamy, an Indian-American entrepreneur who later became a 2024 US presidential candidate, served briefly in the second Trump administration as co-lead of DOGE, exited in January 2025, and now runs Strive Asset Management. Vivek stepped down as Roivant's chief executive in 2021, returned to the board, and Matt Gline, the former chief financial officer, has run the company as CEO since then. Headcount across Roivant and its consolidated subsidiaries sits in the high hundreds, roughly 800 or more depending on how the operating Vants are counted. The defining feature of Roivant is the Vant structure. Rather than running drug programs inside a single corporate parent, Roivant creates wholly owned subsidiary biotech companies, each branded with a Vant suffix, each focused on a specific drug asset, indication, or therapeutic platform, and each with its own management team and operating culture. The corporate hub centralizes capital allocation, business development, regulatory infrastructure, the Roivant Drug Lab, and shared technology platforms such as the Datavant health data linkage business and the Lokavant clinical trial monitoring platform. Notable Vants include Immunovant (NASDAQ: IMVT), the separately listed FcRn antibody company developing batoclimab and IMVT-1402 for myasthenia gravis, Graves' disease, warm autoimmune hemolytic anemia, and other autoimmune indications, which is the single largest value driver in the portfolio. Dermavant developed Vtama (tapinarof), a topical aryl hydrocarbon receptor agonist approved by the FDA in 2022 for plaque psoriasis and later atopic dermatitis, and was sold to Organon in September 2024 for roughly 1.2 billion dollars upfront plus contingent milestones. Other Vants and platforms include Pulmovant in pulmonary disease, Hemavant in myelodysplastic syndromes, Genevant in lipid nanoparticle delivery, Proteovant in protein degradation with Hansoh Pharma, Aerovant, Affivant, Lokavant, and the historical Sumitovant joint venture with Sumitomo Pharma. Roivant's 2024 and 2025 financial story has been dominated by the Vtama monetization. The Organon transaction freed roughly 1.5 billion dollars or more for capital return, and Roivant has executed aggressive share buybacks since, to the point that the equity is sometimes valued by analysts as a sum of its cash position plus its Immunovant stake. This is not a stealth biotech. It is a publicly profiled company whose largest individual shareholder remains a politically prominent figure, whose strategy is openly hub-and-spoke deal-making rather than single-asset purity, and whose biggest near-term clinical catalyst sits inside one specific listed subsidiary. Joining Roivant or any Vant means joining that combined story with eyes open.

Application Process

  1. 1
    Identify which Vant or which Roivant function the role belongs to: an Immunovant

    Identify which Vant or which Roivant function the role belongs to: an Immunovant clinical operations role, a Hemavant medical role, and a Roivant corporate finance role are very different jobs even when they share the careers portal.

  2. 2
    Apply through the Roivant or Vant-specific careers site, which routes to a Green

    Apply through the Roivant or Vant-specific careers site, which routes to a Greenhouse-hosted board at boards.greenhouse.io/roivantsciences for most Roivant and many Vant postings.

  3. 3
    Tailor the resume to the Vant or function: cite the specific therapeutic area, m

    Tailor the resume to the Vant or function: cite the specific therapeutic area, modality, or platform technology in your summary rather than submitting a generic biopharma resume.

  4. 4
    Front-load high-signal experience: clinical development for a launched or late-s

    Front-load high-signal experience: clinical development for a launched or late-stage asset, business development at a biopharma deal shop, FcRn or autoimmune drug experience for Immunovant, dermatology for the legacy Dermavant work, or regulated health data experience for Datavant-adjacent roles.

  5. 5
    Expect a recruiter screen within roughly one to three weeks if your profile matc

    Expect a recruiter screen within roughly one to three weeks if your profile matches an open requisition; quieter periods after large monetization events can stretch this.

  6. 6
    Plan for a hiring manager screen, then a focused panel of three to six interview

    Plan for a hiring manager screen, then a focused panel of three to six interviews depending on level and function, often combining a functional deep dive, a cross-functional partner round, and an executive or general manager round.

  7. 7
    For business development, finance, and corporate strategy roles expect a written

    For business development, finance, and corporate strategy roles expect a written or live case on capital allocation, asset valuation, or deal structuring; Roivant takes deal craft seriously.

  8. 8
    For clinical and regulatory roles expect detailed protocol, endpoint, and statis

    For clinical and regulatory roles expect detailed protocol, endpoint, and statistical methodology questioning, especially for Immunovant given the autoimmune readout cadence.

  9. 9
    A final round with a Vant CEO, a Roivant senior leader, or in some cases Matt Gl

    A final round with a Vant CEO, a Roivant senior leader, or in some cases Matt Gline or a board observer focuses on motivation, fit with the hub-and-spoke model, and willingness to operate inside a deal-driven culture.

  10. 10
    Offer timelines vary by Vant; expect roughly three to eight weeks from first scr

    Offer timelines vary by Vant; expect roughly three to eight weeks from first screen to offer, with compensation frequently structured as base, bonus, and a meaningful equity component in either ROIV or the relevant listed Vant such as IMVT.

Resume Tips for Roivant Sciences

recommended

Lead with measurable biopharma impact: assets advanced, INDs filed, NDAs or BLAs

Lead with measurable biopharma impact: assets advanced, INDs filed, NDAs or BLAs prepared, trial enrollment delivered, market access wins, deals closed in dollars and structure, not vague responsibility statements.

recommended

Name the Vant or platform you are applying to and mirror its language; an Immuno

Name the Vant or platform you are applying to and mirror its language; an Immunovant application that uses the words FcRn, batoclimab, IMVT-1402, myasthenia gravis, and Graves' disease will read very differently from a generic autoimmune resume.

recommended

Cite specific regulators and frameworks honestly: FDA, EMA, MHRA, PMDA, ICH-GCP,

Cite specific regulators and frameworks honestly: FDA, EMA, MHRA, PMDA, ICH-GCP, 21 CFR Part 11, and so on, only where you actually worked under them.

recommended

For business development and corporate roles, list closed transactions with stru

For business development and corporate roles, list closed transactions with structure, counterparty, and your specific role; Roivant culture rewards deal craft and discounts vague involvement.

recommended

For clinical operations, biostatistics, and medical affairs, surface phase-speci

For clinical operations, biostatistics, and medical affairs, surface phase-specific experience and the exact endpoints, indications, and patient populations you have worked on.

recommended

For Datavant or Lokavant adjacent roles, surface real-world data, claims, EHR li

For Datavant or Lokavant adjacent roles, surface real-world data, claims, EHR linkage, tokenization, HIPAA, and de-identification experience explicitly with the systems and standards used.

recommended

Show evidence of working inside small or matrixed teams; Vants are not large pha

Show evidence of working inside small or matrixed teams; Vants are not large pharma, and reviewers screen out candidates who appear to require a deep functional bench underneath them.

recommended

Avoid AI-generated buzzword resumes; reviewers at Roivant and the Vants see a hi

Avoid AI-generated buzzword resumes; reviewers at Roivant and the Vants see a high volume of LLM-augmented submissions and have grown skilled at spotting them.

recommended

Keep formatting clean and ATS-friendly: a single-column PDF in standard fonts, n

Keep formatting clean and ATS-friendly: a single-column PDF in standard fonts, no infographics, no photos for US applications, and a recognizable file name such as Surname_Givenname_Role.pdf.

recommended

Include working hyperlinks to LinkedIn, peer-reviewed publications, regulatory f

Include working hyperlinks to LinkedIn, peer-reviewed publications, regulatory filings you contributed to where citable, and any public presentations at JP Morgan Healthcare, ASH, ASCO, AAN, or similar venues.

ATS System: Greenhouse

Roivant Sciences and most of its Vants post jobs through Greenhouse, with the primary board hosted at boards.greenhouse.io/roivantsciences. Greenhouse is a structured-interview applicant tracking system widely used across biotech and technology employers. It parses resumes, stores structured candidate fields, supports scorecards, and gives recruiters a clean pipeline view. It is well-supported by standard PDF resumes and behaves predictably for most candidates.

  • Submit a single-column PDF with selectable text rather than a scanned image so Greenhouse parses your work history, education, and skills cleanly.
  • Mirror the keywords used in the job description, including specific therapeutic areas, modalities, regulatory frameworks, and technical tools, rather than paraphrased equivalents.
  • Avoid headers, footers, text inside images, multi-column layouts, and graphical elements that often confuse parsers.
  • Use a recognizable file name such as Surname_Givenname_Role.pdf so recruiters can find you in long candidate lists.
  • Fill in the optional Greenhouse fields including LinkedIn URL, location, and how you heard about the role; sparse profiles often score worse in recruiter screens.
  • Include direct working hyperlinks to LinkedIn, publications, and any portfolio or transaction list rather than burying credentials in prose.
  • If you applied to a Vant such as Immunovant directly, do not also blanket the Roivant board for the same role; coordinated applications are preferred and double submissions occasionally trigger duplicate-flagging.

Interview Culture

Roivant's interview culture reflects its hybrid identity as both a deal-making investment platform and a drug development organization.

Loops are direct, intellectually demanding, and weighted toward concrete reasoning rather than credentials or pedigree. For corporate, finance, and business development roles, expect tightly structured cases on asset valuation, deal structuring, capital allocation, and risk-adjusted decision making, often with a written component followed by a live discussion. Reviewers ask why you chose a specific approach, what you would do differently, and what evidence would change your mind. Clinical, regulatory, medical, and statistics interviews focus on the specifics of the indication, the trial design, the endpoint choice, and the regulatory path. Immunovant in particular operates at the leading edge of FcRn biology against argenx Vyvgart, Johnson and Johnson nipocalimab, and other competitors, and candidates should expect detailed questioning on competitive positioning, dose finding, safety monitoring, and the evolving autoimmune treatment landscape. Hand-waving on mechanism, statistics, or competitive context is a fast disqualifier. Culturally, the parent company is more deal-driven and the operating Vants are more drug-development driven. Joining a Vant means joining one specific subsidiary culture more than joining a single Roivant identity. Vant CEOs and general managers vary in style, and your closest manager will shape your day far more than the parent brand. Senior rounds with a Vant CEO, a Roivant senior leader, or Matt Gline focus on motivation, fit with the hub-and-spoke model, and a candid view of where your strengths and gaps actually lie. Working hours are professional rather than performative; the cadence intensifies sharply around clinical readouts, deal closes, and regulatory submissions, and slows in between.

What Roivant Sciences Looks For

  • Demonstrated craft in a specific biopharma function: clinical operations, biostatistics, regulatory affairs, medical affairs, business development, corporate finance, or platform engineering for Datavant and Lokavant adjacent roles, with clear evidence of personal contribution rather than committee credit.
  • Comfort operating inside a small, matrixed organization where individuals own outcomes and cannot rely on a deep functional bench underneath them.
  • Clear capital and commercial judgment, especially for corporate, finance, and business development hires, given Roivant's identity as a deal-making platform with a public market scorecard.
  • Therapeutic area depth where the Vant requires it: autoimmune and FcRn biology for Immunovant, hematology for Hemavant, pulmonary for Pulmovant, dermatology for legacy Dermavant work, MDS and oncology adjacencies for Hemavant.
  • Real-world data, regulated health data, and tokenization experience for Datavant and Lokavant facing roles, with concrete systems and standards rather than buzzwords.
  • Resilience and intellectual honesty about the post-Dermavant capital return story, the political profile of the founder, and the genuine concentration of value in a single listed subsidiary.
  • Willingness to operate at deal pace with ambiguous priorities, frequent reorganizations as Vants are launched, sold, or wound down, and an evolving portfolio surface.
  • Cultural alignment with a culture that values directness, written reasoning, and disagreement based on evidence rather than seniority.
  • Evidence of long-term commitment in prior roles; biotech holding companies are particularly sensitive to talent churn driven by deal-driven hiring cycles.
  • Comfort with public company disclosure norms, including insider trading windows, blackout periods, material non-public information handling, and Regulation FD obligations for any role with access to clinical or financial information.

Frequently Asked Questions

Is Roivant Sciences a good place to build a biopharma career given the hub-and-spoke Vant model?
It depends on what you want. If you want depth in a specific therapeutic area inside a small, focused team with public market visibility, joining a Vant such as Immunovant or Hemavant is a credible choice. If you want broad cross-asset exposure or deal craft, joining the Roivant corporate hub or the business development organization is a stronger fit. If you want to spend a decade on a single asset inside a large pharma, traditional big pharma is a better match.
Does Vivek Ramaswamy still run Roivant Sciences?
No. Vivek Ramaswamy founded Roivant in 2014 and stepped down as chief executive in 2021. Matt Gline, the former chief financial officer, has been CEO since then. Vivek has remained the largest individual shareholder and a public face of the company, ran for US president in 2024, served briefly in the second Trump administration as co-lead of DOGE, exited in January 2025, and now runs Strive Asset Management. Day-to-day operations are run by Matt Gline and the Vant CEOs.
What does it actually mean to join a Vant rather than Roivant itself?
Vants are wholly owned subsidiary biotechs with their own management teams, cultures, and in some cases public listings such as Immunovant. Joining a Vant means joining that specific company's culture, reporting line, and clinical or commercial trajectory. Roivant the parent provides shared infrastructure, capital allocation, and business development support, but your immediate manager, peers, and equity exposure usually sit inside the Vant. Read each Vant's leadership and pipeline carefully before treating Roivant as a single employer.
How does Immunovant compare to argenx and other FcRn competitors as a clinical and commercial bet?
Argenx's Vyvgart, an anti-FcRn antibody, is currently the leading approved FcRn franchise across myasthenia gravis and other indications. Johnson and Johnson's nipocalimab is a direct competitor in development. Immunovant is differentiating on dosing convenience, indication breadth across autoimmune diseases including Graves' disease and warm autoimmune hemolytic anemia, and the IMVT-1402 next-generation profile. Joining Immunovant means joining a competitive race rather than an uncontested market, which is part of the role's intensity and its potential reward.
What happened with the Dermavant sale to Organon and what does it mean for hiring?
Roivant sold Dermavant, the Vant that developed and launched the topical psoriasis and atopic dermatitis treatment Vtama, to Organon in September 2024 for roughly 1.2 billion dollars upfront plus contingent milestones. The transaction sharply reduced Dermavant headcount inside Roivant and freed capital that has been returned to shareholders through aggressive buybacks. Hiring inside the remaining Vants and the Roivant corporate hub continues, but the Dermavant team itself transitioned to Organon.
What ATS does Roivant Sciences use and how should I optimize for it?
Roivant and most of its Vants post through Greenhouse, with the primary board at boards.greenhouse.io/roivantsciences. Greenhouse parses standard PDF resumes well, supports structured scorecards, and gives recruiters a clean pipeline view. Submit a single-column PDF with selectable text, mirror the job description's specific therapeutic and functional language, fill in the optional fields including LinkedIn URL and source attribution, and use a recognizable file name. Avoid graphics, photos for US submissions, and multi-column layouts.
How political is the work environment given Vivek Ramaswamy's public profile?
Day-to-day operations are not partisan. Matt Gline runs the company, Vant CEOs run the operating biotechs, and the work itself is biopharmaceutical drug development and deal-making. That said, Vivek Ramaswamy's 2024 presidential campaign, his role at DOGE, and his current Strive Asset Management work are part of the public conversation around Roivant, and the topic occasionally surfaces in interviews and external press. Treat questions about it candidly and bring your own values to the conversation rather than pretending the context is invisible.
What is the compensation structure typically like at Roivant and the Vants?
Compensation typically combines a competitive base salary, a performance bonus tied to corporate or Vant-level milestones, and a meaningful equity grant. For Roivant corporate roles equity is in ROIV. For some Vant-specific roles, particularly inside the listed Immunovant, equity may be in the Vant ticker such as IMVT. Senior business development, finance, and Vant CEO roles can carry significant carry-equivalent or performance-share structures. Public company disclosure obligations including insider trading windows and blackout periods apply to any role with access to material non-public information.
How does Roivant compare to other hub-and-spoke biotech holding companies as an employer?
BridgeBio Pharma, Centessa Pharmaceuticals, and PureTech Health all run variants of the multi-asset, subsidiary-driven model with different therapeutic focuses and funding postures. BridgeBio is more genetic-disease focused and ran a major BB-2603 ATTR cardiomyopathy launch. Centessa runs a broader subsidiary portfolio. PureTech operates more like an evergreen incubator. Roivant is distinguished by its scale of capital return through buybacks, its prior Vtama monetization, and the political profile of its founder. Compensation and culture vary noticeably across these peers; treat them as related but not interchangeable.
What is the biggest risk to Roivant Sciences as a place to build a career right now?
The single largest risk is concentration of value in Immunovant. With Dermavant sold, much of the equity story rides on Immunovant's clinical readouts in batoclimab and IMVT-1402 against well-funded competitors, particularly argenx. A negative readout or a competitive setback would reshape the parent company's market value and almost certainly the broader Vant portfolio's hiring posture. Joining Roivant or any Vant means joining that risk profile with eyes open. Aggressive buybacks have reduced share count meaningfully and concentrated remaining shareholders' exposure to that same outcome.
What should I avoid doing during the Roivant interview process?
Avoid pretending the founder's political profile or the hub-and-spoke model are invisible; reviewers value candor. Avoid generic biopharma framing; tailor to the specific Vant and function. Avoid hand-waving on clinical, statistical, or financial specifics; reviewers probe quickly. Avoid AI-generated resume text; it is widely recognized. Avoid claiming credit for committee outcomes you did not personally drive. And avoid treating the parent brand and a specific Vant as interchangeable; your day-to-day will be shaped by the Vant you actually join.

Open Positions

Roivant Sciences currently has 11 open positions.

Check Your Resume Before Applying → View 11 open positions at Roivant Sciences

Related Resources

Similar Companies

Related Articles

Sources

  1. Roivant Sciences Official Website —
  2. Roivant Sciences Careers (Greenhouse Board) —
  3. Roivant Sciences Ltd. (ROIV) on NASDAQ —
  4. Immunovant, Inc. (IMVT) Investor Relations —
  5. Organon to Acquire Dermavant Sciences (Sept 2024 announcement) —
  6. Roivant Sciences SEC Filings (EDGAR) —
  7. Datavant Corporate Site —
  8. Lokavant Corporate Site —
  9. Vtama (tapinarof) FDA Approval History —
  10. Matt Gline Profile, Roivant Leadership —
  11. Vivek Ramaswamy Wikipedia (background and Roivant founding) —
  12. Argenx Vyvgart (efgartigimod) Product Information (FcRn competitive context) —
  13. BridgeBio Pharma (peer hub-and-spoke biotech holding) —
  14. Centessa Pharmaceuticals (peer hub-and-spoke biotech holding) —